Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $30.44M rose 18.2% year over year, behind the +41.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 16.7% from the prior quarter. Over 3 fiscal years it compounded at -8.1% a year.

Context

  • Selling, general & admin amounted to 45.5% of revenue in FY2025, down 21.0 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $100.31M (-6.7%) for the fiscal year ending Dec 2026, a slowdown from the +0.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.44M+16.7% QoQ
Last fiscal yearDec 2025
$107.48M+0.9% YoY
LTMMar 2026
$113.07M+41.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.2%+7.9%-10.4 pp
1 year+0.9%-6.7%-7.5 pp
3-year CAGR-8.1%-16.7%-8.5 pp
5-year CAGR-4.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
107.48M USD
Year-over-year change
+0.9%
4-year CAGR
-11.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 selling, general & admin of $113.07M is the 3rd highest of the 10 companies compared; the peer median is $47.81M.
  • Its year-over-year change of +41.5% is the 2nd highest of 9, against a peer median of +16.3%.
  • Selling, general & admin amounts to 48.7% of revenue for AKBA, versus a peer median of 75.2%.
AKBA Competitors Peer median
Selling, General & Admin for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$198.25M ——171.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M +5.8%+1.0%39.6%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$113.07M +41.5%-8.1%48.7%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$78.85M +22.3%+72.8%64.5%
PRTAProthena Corporation plcLTM Mar 2026$54.46M -19.1%+6.0%94.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$47.81M -5.9%+14.2%54.2%
GOSSGossamer Bio, Inc.LTM Mar 2026$47.72M +35.5%-7.5%85.9%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$25.39M +44.8%-5.3%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M +10.2%+13.1%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M +24.0%+4.5%—
Peer median (excluding AKBA) $47.81M+16.3%+5.3%75.2%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.